Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-11-25
1998-12-01
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 16, A61K 3724
Patent
active
058439021
ABSTRACT:
Methods for treating prostate cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys prostatic tumor tissue, such as a radical prostatectomy, cryosurgery or radiation therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH agonist, either simultaneous with or subsequent to LHRH antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex steroid biosynthesis to the subject in combination with the LHRH antagonist. Methods for inhibiting the LHRH agonist-induced hormone surge, whatever its clinical setting, are also disclosed. These methods generally involve administration of an LHRH-antagonist in combination with the LHRH agonist. Complete suppression of the LHRH agonist-induced hormone surge has been achieved by pretreatment with a sustained-release formulation of LHRH antagonist.
REFERENCES:
patent: 4659695 (1987-04-01), Labrie
patent: 4666885 (1987-05-01), Labrie
patent: 4760053 (1988-07-01), Labrie
patent: 4775660 (1988-10-01), Labrie et al.
patent: 4775661 (1988-10-01), Labrie
patent: 5023234 (1991-06-01), Labrie
patent: 5064813 (1991-11-01), Labrie
patent: 5116615 (1992-05-01), Gokcen et al.
patent: 5130137 (1992-07-01), Crowley, Jr.
patent: 5180711 (1993-01-01), Hodgen
patent: 5372996 (1994-12-01), Labrie
Andros, E. et al., "Neoadjuvant Hormonal Therapy in Stage C Adenocarcinoma of the Prostrate," Clin. Invest. Med. vol. 16:6, 510-515 (1993).
Couzinet, B. et al. "Effects of Gonadotrophin Releasing Hormone Anatagonist and Agonist on the Pulsatile Release of Gonadotrophins and X-Subunit in Postmenopausal Women," Clinical Endocrinologyvol. 34, 477-483 (1991).
Illions, E. et al., "Evaluation of the Impact of Concurrent Gonadotropin-Releasing Hormone (GnRH) Antagonist Administration on GnRH Agonist-Induced Gonadotrope Desensitization," Fertility and Sterility, vol. 64:4, 848-854 (1995).
Emons, Gunter et al. "The Use of Luteinizing Hormone Releasing Hormone Agonists and Antagonists In Gynaecological Cancers", Human Reproduction Update, vol. 9, No. 7, pp. 1364-1379, 1994.
Pinski, J. et al., "Blockade of the LH Response Induced by the Agonist D-Trp-6-LHRH in Rats by a Highly Potent LH-RH Anataonist SB-75," The Prostatevol. 20, 213-224 (1992).
Pinski, Jacek et al. "Inhibitory Effects of Analogs of Luteinizing Hormone-Releasing Hormone On The Growth of The Androgen-Independent Dunning R-3327-AT-1 Rat Prostate Cancer", Int. J. Cancer: 59, 51-55 (1994).
Labrie, F. et al., "Combination Therapy for Prostate Cancer," Cancer Supplement vol. 71:3, 1059-1067 (1993).
Labrie, F. et al., "Downstaging by Combination Therapy with Flutamide and an LHRH Agonist before Radical Prostatectomy," Cancer Surveys vol. 23, 149-156 (1995).
Sharma, O.P. et al., "The Gonadotropin-Releasing Hormone (GnRH) Agonist-Induced Initial Rise of Bioactive LH and Testosterone can be Blunted in a Dose-Dependent Manner by GnRH Antagonist in the Non-Human Primate," Urological Research vol. 20, 317-321 (1992).
Smith, P.H. et al., "Hormone Therapy: An Overview," Cancer Surveys vol. 23, 171-181 (1995).
Solomon, M.H. et al., "Hormone Ablation Therapy as Neoadjuvant Treatment to Radical Prostatectomy," Clin. Invest. Med. vol. 16:6, 532-538 (1993).
Garnick Marc B.
Gefter Malcolm L.
Molineaux Christopher J.
DeConti, Jr. Giulio A.
Kara Catherine J.
Praecis Pharmaceuticals Incorporated
Raymond Richard L.
LandOfFree
Methods for treating prostate cancer with LHRH antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating prostate cancer with LHRH antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating prostate cancer with LHRH antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2395672